Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients

Table 6 Comparative results of statistically significant (p < 0.05) prognostic factors in major studies reported worldwide and compared to this study

Study	Leblond et al. [23]	Jain et al. [24]	Ghobrial et al. [25]	Maecker et al. [26]	Oton et al. [27]	Knight et al. [28]	Evens et al. [29]	Kinch et al. [30]	Dierickx et al. [31]	Montanari et al. [32]	Luskin et al. [33]	This study
Year	2001	2002	2005	2007	2008	2009	2010	2013	2013	2015	2015	2017
Subjects (n)	61	170	107	55	84	78	80	135	140	120	176	141
Advanced age at diagnosis	NSS	NSS	SS					SS	SS	SS	SS	SS
Performance status	SS		SS		SS	NSS	SS	SS	SS	SS		SS
Late PTLD onset	Poor (NSS)	NSS	NSS	NSS	Good (SS)		NSS		NSS	NSS		NSS
Gender	NSS	F > M (NSS)	NSS					NSS		NSS		F > M (SS)
Extra-nodal site	SS		SS	SS	SS	NSS	SS	SS	SS	NSS	SS	SS
CD20 +			NSS						NSS	SS		NSS
Low albumin							SS		SS	NSS		NSS
High LDH	NSS		SS				NSS	SS	SS	NSS	SS	NSS
B-symptoms						NSS		SS			NSS	NSS
Allograft type	NSS		NSS	NSS				SS		NSS	SS	SS
Non EBV PTLD	SS	NSS		NS				SS		NSS	NSS	NSS
Advanced stage	NS		SS	SS	SS	SS	NSS	SS	SS	NSS	SS	NSS
PTLD type/grade	NSS	SS		NSS					SS	NSS	NSS	SS
Higher IPI	NSS		SS			SS	NSS		SS			SS
Initial response			SS	SS								SS
Rituximab use			NSS		SS		SS			NSS		NSS

ISSN: 2162-3619